Abstract
The rewiring of metabolic pathways is one of the hallmarks of cancer and essential for tumorigenesis. It stems from the need of cancer cells to adapt their biosynthetic and bioenergetic demands in order to allow unrestricted proliferation and growth. Melanoma and other cancer cells exhibit a remarkable flexibility within a complex network of metabolic pathways, allowing them to use their often limited resources and direct them to the processes best placed to maximize their growth and survival. For example, during melanomagenesis, cells will often switch their energy production from mitochondrial metabolism to glycolysis, because the products of glycolysis can easily be shifted to essential pathways for macromolecule biosynthesis. Many of these metabolic alterations are initiated in response to signaling cues from genetic alterations that initiated melanomagenesis in the first place, which suggests that the events required to transform cells to malignancy must allow cells to meet their biosynthetic and bioenergetic needs. During progression, melanomas appear to display metabolic heterogeneity as vital nutrient sources become scarce and the tumor seeks to overcome these restrictions. As further insights into the metabolic rewiring that occurs during melanoma development and progression are gained, opportunities to target these vulnerabilities for therapeutic benefit may be exploited.
This book chapter provides a brief overview of important metabolic pathways and how these become reprogrammed by known oncogenes that are frequently altered in human melanomas. How these metabolic vulnerabilities are being targeted for clinical use will also be highlighted.
This is a preview of subscription content, log in via an institution to check access.
References
Allen E, Mieville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D (2016) Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep 15(6):1144–1160. https://doi.org/10.1016/j.celrep.2016.04.029
Baenke F, Peck B, Miess H, Schulze A (2013) Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech 6(6):1353–1363. https://doi.org/10.1242/dmm.011338
Baenke F, Chaneton B, Smith M, Van Den Broek N, Hogan K, Tang H, Viros A, Martin M, Galbraith L, Girotti MR, Dhomen N, Gottlieb E, Marais R (2016) Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells. Mol Oncol 10(1):73–84. https://doi.org/10.1016/j.molonc.2015.08.003
Bedogni B, Powell MB (2009) Hypoxia, melanocytes and melanoma – survival and tumor development in the permissive microenvironment of the skin. Pigment Cell Melanoma Res 22(2):166–174. https://doi.org/10.1111/j.1755-148X.2009.00553.x
Bensaad K, Tsuruta A, Selak MA, Vidal MN, Nakano K, Bartrons R, Gottlieb E, Vousden KH (2006) TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 126(1):107–120. https://doi.org/10.1016/j.cell.2006.05.036
Bettum IJ, Gorad SS, Barkovskaya A, Pettersen S, Moestue SA, Vasiliauskaite K, Tenstad E, Oyjord T, Risa O, Nygaard V, Maelandsmo GM, Prasmickaite L (2015) Metabolic reprogramming supports the invasive phenotype in malignant melanoma. Cancer Lett 366(1):71–83. https://doi.org/10.1016/j.canlet.2015.06.006
Bohme I, Bosserhoff AK (2016) Acidic tumor microenvironment in human melanoma. Pigment Cell Melanoma Res. https://doi.org/10.1111/pcmr.12495
Boroughs LK, DeBerardinis RJ (2015) Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol 17(4):351–359. https://doi.org/10.1038/ncb3124
Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ, Tonc E, Schreiber RD, Pearce EJ, Pearce EL (2015a) Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162(6):1229–1241. https://doi.org/10.1016/j.cell.2015.08.016
Chang YL, Gao HW, Chiang CP, Wang WM, Huang SM, Ku CF, Liu GY, Hung HC (2015b) Human mitochondrial NAD(P)(+)-dependent malic enzyme participates in cutaneous melanoma progression and invasion. J Invest Dermatol 135(3):807–815. https://doi.org/10.1038/jid.2014.385
Damsky W, Micevic G, Meeth K, Muthusamy V, Curley DP, Santhanakrishnan M, Erdelyi I, Platt JT, Huang L, Theodosakis N, Zaidi MR, Tighe S, Davies MA, Dankort D, McMahon M, Merlino G, Bardeesy N, Bosenberg M (2015) mTORC1 activation blocks BrafV600E-induced growth arrest but is insufficient for melanoma formation. Cancer Cell 27(1):41–56. https://doi.org/10.1016/j.ccell.2014.11.014
DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA, Tuveson DA (2011) Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 475(7354):106–109. https://doi.org/10.1038/nature10189
DeNicola GM, Chen PH, Mullarky E, Sudderth JA, Hu Z, Wu D, Tang H, Xie Y, Asara JM, Huffman KE, Wistuba II, Minna JD, DeBerardinis RJ, Cantley LC (2015) NRF2 regulates serine biosynthesis in non-small cell lung cancer. Nat Genet 47(12):1475–1481. https://doi.org/10.1038/ng.3421
Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS (2006) Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway. Nat Cell Biol 8(10):1053–1063. https://doi.org/10.1038/ncb1471
Efeyan A, Comb WC, Sabatini DM (2015) Nutrient-sensing mechanisms and pathways. Nature 517(7534):302–310. https://doi.org/10.1038/nature14190
Falck Miniotis M, Arunan V, Eykyn TR, Marais R, Workman P, Leach MO, Beloueche-Babari M (2013) MEK1/2 inhibition decreases lactate in BRAF-driven human cancer cells. Cancer Res 73(13):4039–4049. https://doi.org/10.1158/0008-5472.CAN-12-1969
Filipp FV, Ratnikov B, De Ingeniis J, Smith JW, Osterman AL, Scott DA (2012a) Glutamine-fueled mitochondrial metabolism is decoupled from glycolysis in melanoma. Pigment Cell Melanoma Res 25(6):732–739. https://doi.org/10.1111/pcmr.12000
Filipp FV, Scott DA, Ronai ZA, Osterman AL, Smith JW (2012b) Reverse TCA cycle flux through isocitrate dehydrogenases 1 and 2 is required for lipogenesis in hypoxic melanoma cells. Pigment Cell Melanoma Res 25(3):375–383. https://doi.org/10.1111/j.1755-148X.2012.00989.x
Flier JS, Mueckler MM, Usher P, Lodish HF (1987) Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. Science 235(4795):1492–1495
Garcia-Cao I, Song MS, Hobbs RM, Laurent G, Giorgi C, de Boer VC, Anastasiou D, Ito K, Sasaki AT, Rameh L, Carracedo A, Vander Heiden MG, Cantley LC, Pinton P, Haigis MC, Pandolfi PP (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149(1):49–62. https://doi.org/10.1016/j.cell.2012.02.030
Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12):931–947. https://doi.org/10.1038/nrd4002
Haq R, Shoag J, Andreu-Perez P, Yokoyama S, Edelman H, Rowe GC, Frederick DT, Hurley AD, Nellore A, Kung AL, Wargo JA, Song JS, Fisher DE, Arany Z, Widlund HR (2013) Oncogenic BRAF regulates oxidative metabolism via PGC1alpha and MITF. Cancer Cell 23(3):302–315. https://doi.org/10.1016/j.ccr.2013.02.003
Harris IS, Treloar AE, Inoue S, Sasaki M, Gorrini C, Lee KC, Yung KY, Brenner D, Knobbe-Thomsen CB, Cox MA, Elia A, Berger T, Cescon DW, Adeoye A, Brustle A, Molyneux SD, Mason JM, Li WY, Yamamoto K, Wakeham A, Berman HK, Khokha R, Done SJ, Kavanagh TJ, Lam CW, Mak TW (2015) Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. Cancer Cell 27(2):211–222. https://doi.org/10.1016/j.ccell.2014.11.019
Hirata E, Girotti MR, Viros A, Hooper S, Spencer-Dene B, Matsuda M, Larkin J, Marais R, Sahai E (2015) Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin beta1/FAK signaling. Cancer Cell 27(4):574–588. https://doi.org/10.1016/j.ccell.2015.03.008
Israelsen WJ, Vander Heiden MG (2015) Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol 43:43–51. https://doi.org/10.1016/j.semcdb.2015.08.004
Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, Kafri R, Kirschner MW, Clish CB, Mootha VK (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084):1040–1044. https://doi.org/10.1126/science.1218595
Jiang P, Du W, Mancuso A, Wellen KE, Yang X (2013) Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature 493(7434):689–693. https://doi.org/10.1038/nature11776
Kamphorst JJ, Cross JR, Fan J, de Stanchina E, Mathew R, White EP, Thompson CB, Rabinowitz JD (2013) Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc Natl Acad Sci U S A 110(22):8882–8887. https://doi.org/10.1073/pnas.1307237110
Kang HB, Fan J, Lin R, Elf S, Ji Q, Zhao L, Jin L, Seo JH, Shan C, Arbiser JL, Cohen C, Brat D, Miziorko HM, Kim E, Abdel-Wahab O, Merghoub T, Frohling S, Scholl C, Tamayo P, Barbie DA, Zhou L, Pollack BP, Fisher K, Kudchadkar RR, Lawson DH, Sica G, Rossi M, Lonial S, Khoury HJ, Khuri FR, Lee BH, Boggon TJ, He C, Kang S, Chen J (2015) Metabolic rewiring by oncogenic BRAF V600E links ketogenesis pathway to BRAF-MEK1 signaling. Mol Cell 59(3):345–358. https://doi.org/10.1016/j.molcel.2015.05.037
Kaplon J, Zheng L, Meissl K, Chaneton B, Selivanov VA, Mackay G, van der Burg SH, Verdegaal EM, Cascante M, Shlomi T, Gottlieb E, Peeper DS (2013) A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. Nature 498(7452):109–112. https://doi.org/10.1038/nature12154
Kardos GR, Wastyk HC, Robertson GP (2015) Disruption of proline synthesis in melanoma inhibits protein production mediated by the GCN2 pathway. Mol Cancer Res 13(10):1408–1420. https://doi.org/10.1158/1541-7786.MCR-15-0048
Keith B, Johnson RS, Simon MC (2012) HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer 12(1):9–22. https://doi.org/10.1038/nrc3183
Kluza J, Corazao-Rozas P, Touil Y, Jendoubi M, Maire C, Guerreschi P, Jonneaux A, Ballot C, Balayssac S, Valable S, Corroyer-Dulmont A, Bernaudin M, Malet-Martino M, de Lassalle EM, Maboudou P, Formstecher P, Polakowska R, Mortier L, Marchetti P (2012) Inactivation of the HIF-1alpha/PDK3 signaling axis drives melanoma toward mitochondrial oxidative metabolism and potentiates the therapeutic activity of pro-oxidants. Cancer Res 72(19):5035–5047. https://doi.org/10.1158/0008-5472.CAN-12-0979
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS (2010) The essence of senescence. Genes Dev 24(22):2463–79
LaGory EL, Giaccia AJ (2016) The ever-expanding role of HIF in tumour and stromal biology. Nat Cell Biol 18(4):356–365. https://doi.org/10.1038/ncb3330
Lakhter AJ, Hamilton J, Konger RL, Brustovetsky N, Broxmeyer HE, Naidu SR (2016) Glucose-independent acetate metabolism promotes melanoma cell survival and tumor growth. J Biol Chem. https://doi.org/10.1074/jbc.M115.712166
Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293. https://doi.org/10.1016/j.cell.2012.03.017
Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, Dalin MG, Akyurek LM, Lindahl P, Nilsson J, Bergo MO (2015) Antioxidants can increase melanoma metastasis in mice. Sci Transl Med 7(308):308re308. https://doi.org/10.1126/scitranslmed.aad3740
LeBleu VS, O'Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, de Carvalho FM, Damascena A, Domingos Chinen LT, Rocha RM, Asara JM, Kalluri R (2014) PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol 16(10):992–1003., , 1001–1015. https://doi.org/10.1038/ncb3039
Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, Finkel T (1999) Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274(12):7936–7940
Lim JH, Luo C, Vazquez F, Puigserver P (2014) Targeting mitochondrial oxidative metabolism in melanoma causes metabolic compensation through glucose and glutamine utilization. Cancer Res 74(13):3535–3545. https://doi.org/10.1158/0008-5472.CAN-13-2893-T
Liu W, Beck BH, Vaidya KS, Nash KT, Feeley KP, Ballinger SW, Pounds KM, Denning WL, Diers AR, Landar A, Dhar A, Iwakuma T, Welch DR (2014) Metastasis suppressor KISS1 seems to reverse the Warburg effect by enhancing mitochondrial biogenesis. Cancer Res 74(3):954–963. https://doi.org/10.1158/0008-5472.CAN-13-1183
Locasale JW, Grassian AR, Melman T, Lyssiotis CA, Mattaini KR, Bass AJ, Heffron G, Metallo CM, Muranen T, Sharfi H, Sasaki AT, Anastasiou D, Mullarky E, Vokes NI, Sasaki M, Beroukhim R, Stephanopoulos G, Ligon AH, Meyerson M, Richardson AL, Chin L, Wagner G, Asara JM, Brugge JS, Cantley LC, Vander Heiden MG (2011) Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet 43(9):869–874. https://doi.org/10.1038/ng.890
Ma XH, Piao SF, Dey S, McAfee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J, Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Xu W, Schuchter LM, Davies MA, Herlyn M, Winkler J, Koumenis C, Amaravadi RK (2014) Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma. J Clin Invest 124(3):1406–1417. https://doi.org/10.1172/JCI70454
Maddocks OD, Berkers CR, Mason SM, Zheng L, Blyth K, Gottlieb E, Vousden KH (2013) Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493(7433):542–546. https://doi.org/10.1038/nature11743
Maes H, Kuchnio A, Peric A, Moens S, Nys K, De Bock K, Quaegebeur A, Schoors S, Georgiadou M, Wouters J, Vinckier S, Vankelecom H, Garmyn M, Vion AC, Radtke F, Boulanger C, Gerhardt H, Dejana E, Dewerchin M, Ghesquiere B, Annaert W, Agostinis P, Carmeliet P (2014) Tumor vessel normalization by chloroquine independent of autophagy. Cancer Cell 26(2):190–206. https://doi.org/10.1016/j.ccr.2014.06.025
Mashimo T, Pichumani K, Vemireddy V, Hatanpaa KJ, Singh DK, Sirasanagandla S, Nannepaga S, Piccirillo SG, Kovacs Z, Foong C, Huang Z, Barnett S, Mickey BE, DeBerardinis RJ, Tu BP, Maher EA, Bachoo RM (2014) Acetate is a bioenergetic substrate for human glioblastoma and brain metastases. Cell 159(7):1603–1614. https://doi.org/10.1016/j.cell.2014.11.025
Mullen AR, Wheaton WW, Jin ES, Chen PH, Sullivan LB, Cheng T, Yang Y, Linehan WM, Chandel NS, DeBerardinis RJ (2012) Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 481(7381):385–388. https://doi.org/10.1038/nature10642
Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF (2010) Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 140(1):49–61. https://doi.org/10.1016/j.cell.2009.11.027
Nowicki S, Gottlieb E (2015) Oncometabolites: tailoring our genes. FEBS J 282(15):2796–2805. https://doi.org/10.1111/febs.13295
Parmenter TJ, Kleinschmidt M, Kinross KM, Bond ST, Li J, Kaadige MR, Rao A, Sheppard KE, Hugo W, Pupo GM, Pearson RB, McGee SL, Long GV, Scolyer RA, Rizos H, Lo RS, Cullinane C, Ayer DE, Ribas A, Johnstone RW, Hicks RJ, McArthur GA (2014) Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. https://doi.org/10.1158/2159-8290.CD-13-0440
Pinheiro C, Miranda-Goncalves V, Longatto-Filho A, Vicente AL, Berardinelli GN, Scapulatempo-Neto C, Costa RF, Viana CR, Reis RM, Baltazar F, Vazquez VL (2016) The metabolic microenvironment of melanomas: prognostic value of MCT1 and MCT4. Cell Cycle 15(11):1462–1470. https://doi.org/10.1080/15384101.2016.1175258
Pisarsky L, Bill R, Fagiani E, Dimeloe S, Goosen RW, Hagmann J, Hess C, Christofori G (2016) Targeting metabolic symbiosis to overcome resistance to anti-angiogenic therapy. Cell Rep 15(6):1161–1174. https://doi.org/10.1016/j.celrep.2016.04.028
Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z (2015) Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 527(7577):186–91
Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J, Salem G, Pohida T, Heenan P, Duray P, Kallioniemi O, Hayward NK, Trent JM, Meltzer PS (2003) High frequency of BRAF mutations in nevi. Nat Genet 33(1):19–20. https://doi.org/10.1038/ng1054
Rohrig F, Schulze A (2016) The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. https://doi.org/10.1038/nrc.2016.89
Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO (2014) Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 6(221):221ra215. https://doi.org/10.1126/scitranslmed.3007653
Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E, Mason S, Blyth K, McGarry L, James D, Shanks E, Kalna G, Saunders RE, Jiang M, Howell M, Lassailly F, Thin MZ, Spencer-Dene B, Stamp G, van den Broek NJ, Mackay G, Bulusu V, Kamphorst JJ, Tardito S, Strachan D, Harris AL, Aboagye EO, Critchlow SE, Wakelam MJ, Schulze A, Gottlieb E (2015) Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell 27(1):57–71. https://doi.org/10.1016/j.ccell.2014.12.002
Scott DA, Richardson AD, Filipp FV, Knutzen CA, Chiang GG, Ronai ZA, Osterman AL, Smith JW (2011) Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem 286(49):42626–42634. https://doi.org/10.1074/jbc.M111.282046
Seguin F, Carvalho MA, Bastos DC, Agostini M, Zecchin KG, Alvarez-Flores MP, Chudzinski-Tavassi AM, Coletta RD, Graner E (2012) The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas. Br J Cancer 107(6):977–987. https://doi.org/10.1038/bjc.2012.355
Sheen JH, Zoncu R, Kim D, Sabatini DM (2011) Defective regulation of autophagy upon leucine deprivation reveals a targetable liability of human melanoma cells in vitro and in vivo. Cancer Cell 19(5):613–628. https://doi.org/10.1016/j.ccr.2011.03.012
Shin S, Buel GR, Wolgamott L, Plas DR, Asara JM, Blenis J, Yoon SO (2015) ERK2 mediates metabolic stress response to regulate cell fate. Mol Cell 59(3):382–398. https://doi.org/10.1016/j.molcel.2015.06.020
Shoag J, Haq R, Zhang M, Liu L, Rowe GC, Jiang A, Koulisis N, Farrel C, Amos CI, Wei Q, Lee JE, Zhang J, Kupper TS, Qureshi AA, Cui R, Han J, Fisher DE, Arany Z (2012) PGC-1 coactivators regulate MITF and the tanning response. Mol Cell. doi: S1097-2765(12)00908-2 [pii]. https://doi.org/10.1016/j.molcel.2012.10.027
Slominski A, Kim TK, Brozyna AA, Janjetovic Z, Brooks DL, Schwab LP, Skobowiat C, Jozwicki W, Seagroves TN (2014) The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways. Arch Biochem Biophys 563:79–93. https://doi.org/10.1016/j.abb.2014.06.030
Sporn MB, Liby KT (2012) NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12(8):564–571. https://doi.org/10.1038/nrc3278
Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, Prives C (2010) Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci U S A 107(16):7461–7466. https://doi.org/10.1073/pnas.1002459107
Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, Eaton JW, Chesney J (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25(55):7225–7234. https://doi.org/10.1038/sj.onc.1209709
Vander Heiden MG (2011) Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 10(9):671–684. https://doi.org/10.1038/nrd3504
Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, Vokes NI, Stephanopoulos G, Cantley LC, Metallo CM, Locasale JW (2011) Metabolic pathway alterations that support cell proliferation. Cold Spring Harb Symp Quant Biol 76:325–334. https://doi.org/10.1101/sqb.2012.76.010900. sqb.2012.76.010900 [pii]
Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, Clish CB, Granter SR, Widlund HR, Spiegelman BM, Puigserver P (2013) PGC1alpha expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell 23(3):287–301. https://doi.org/10.1016/j.ccr.2012.11.020
Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS (2012) Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Genes Dev 26(10):1055–1069. https://doi.org/10.1101/gad.187252.112
Wang Q, Beaumont KA, Otte NJ, Font J, Bailey CG, van Geldermalsen M, Sharp DM, Tiffen JC, Ryan RM, Jormakka M, Haass NK, Rasko JE, Holst J (2014) Targeting glutamine transport to suppress melanoma cell growth. Int J Cancer. https://doi.org/10.1002/ijc.28749
Warburg O (1924) On the metabolism of cancer cells. Naturwissenschaften 12:1131–1137
Warita K, Warita T, Beckwitt CH, Schurdak ME, Vazquez A, Wells A, Oltvai ZN (2014) Statin-induced mevalonate pathway inhibition attenuates the growth of mesenchymal-like cancer cells that lack functional E-cadherin mediated cell cohesion. Sci Rep 4:7593. https://doi.org/10.1038/srep07593
Wawrzyniak JA, Bianchi-Smiraglia A, Bshara W, Mannava S, Ackroyd J, Bagati A, Omilian AR, Im M, Fedtsova N, Miecznikowski JC, Moparthy KC, Zucker SN, Zhu Q, Kozlova NI, Berman AE, Hoek KS, Gudkov AV, Shewach DS, Morrison CD, Nikiforov MA (2013) A purine nucleotide biosynthesis enzyme guanosine monophosphate reductase is a suppressor of melanoma invasion. Cell Rep 5(2):493–507. https://doi.org/10.1016/j.celrep.2013.09.015
White E (2012) Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer 12(6):401–410. https://doi.org/10.1038/nrc3262
Xie X, Koh JY, Price S, White E, Mehnert JM (2015) Atg7 overcomes senescence and promotes growth of BrafV600E-driven melanoma. Cancer Discov 5(4):410–423. https://doi.org/10.1158/2159-8290.CD-14-1473
Yuan P, Ito K, Perez-Lorenzo R, Del Guzzo C, Lee JH, Shen CH, Bosenberg MW, McMahon M, Cantley LC, Zheng B (2013) Phenformin enhances the therapeutic benefit of BRAF(V600E) inhibition in melanoma. Proc Natl Acad Sci U S A 110(45):18226–18231. https://doi.org/10.1073/pnas.1317577110
Zelenay S, van der Veen AG, Bottcher JP, Snelgrove KJ, Rogers N, Acton SE, Chakravarty P, Girotti MR, Marais R, Quezada SA, Sahai E, Reis ESC (2015) Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162(6):1257–1270. https://doi.org/10.1016/j.cell.2015.08.015
Zhang J, Fan J, Venneti S, Cross JR, Takagi T, Bhinder B (2014) Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion. Mol Cell 56(2):205–18
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media LLC
About this entry
Cite this entry
Baenke, F., Dhomen, N., Gottlieb, E., Marais, R. (2018). Metabolism: The Sweet Spot in Melanoma Precision Medicine?. In: Fisher, D., Bastian, B. (eds) Melanoma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7322-0_28-1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7322-0_28-1
Received:
Accepted:
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7322-0
Online ISBN: 978-1-4614-7322-0
eBook Packages: Springer Reference MedicineReference Module Medicine
Publish with us
Chapter history
-
Latest
Melanoma Metabolism- Published:
- 05 June 2019
DOI: https://doi.org/10.1007/978-1-4614-7322-0_28-2
-
Original
Metabolism: The Sweet Spot in Melanoma Precision Medicine?- Published:
- 25 October 2017
DOI: https://doi.org/10.1007/978-1-4614-7322-0_28-1